NCT00566098View on ClinicalTrials.gov

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2014

Study Completion Date

October 31, 2018

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

MILs

DRUG

Melphalan

BIOLOGICAL

PCV13

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00566098 - Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter